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Abstract
We previously observed that changes in choline phos-
pholipids of two malignant human mammary epithelial
cells (HMECs) following treatment with a high dose of
the cyclooxygenase (COX) inhibitor, indomethacin,
mimicked changes following transfection with a meta-
stasis suppressor gene, nm23. The similarity between
response to indomethacin and nm23 transfection led us
to 1) expand our 1H NMR spectroscopy study of
indomethacin treatment by determining the response
at two doses for two nonmalignant and three malignant
HMECs, 2) investigate COX-1 and COX-2 levels in
HMECs and their relationship with choline phosholipid
metabolites, and 3) determine changes in Nm23 ex-
pression following treatment with indomethacin. All
HMECs exhibited a significant change in choline
phospholipids following treatment with 300 mM indo-
methacin. At the lower dose of 50 mM, only nonmalig-
nant HMECs and the estrogen-dependent malignant cell
line, MCF-7, responded. COX-1 levels were significantly
higher in malignant HMECs than in nonmalignant
HMECs. A significant increase in Nm23 expression
following 300 mM indomethacin was detected in MCF-
12A and MCF-7 cells but not in MDA-MB-231 and MDA-
MB-435 cells. These results suggest that COX-1
expression and its inhibition play a role in the choline
phospholipid metabolism of HMECs, and the effect of
indomethacin on HMECs may be mediated, in part,
through upregulation of nm23.
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Introduction
Nuclear magnetic resonance spectroscopy has been
employed to study choline phospholipid metabolism of breast
cancers in vivo, breast cancer cells, and excised tissue.
These studies have clearly demonstrated that, compared to
normal tissue, the choline phospholipid metabolism of human
breast cancer is significantly different [1–4].
Our NMR studies of human mammary epithelial cells
(HMECs) have also revealed distinct alterations in choline
phospholipid metabolites of highly malignant breast cancer
cells. We observed that nm23 - transfected MDA-MB-435
cells, and transgene tumors derived from these cells,
showed significantly lower ratios of phosphorylcholine (PC)
to glycerophosphorylcholine (GPC), compared to vector-
transfected control cells and tumors [5]. Breast cancer
studies have shown that low expression levels of nm23 RNA
and protein correlate with high metastatic potential [6,7 ]. In
vitro experiments using cancer cells transfected with nm23
have also established that nm23 expression alters the
motility, invasiveness, and colonization of cancer cells and
reduces the metastatic potential of these cells [8,9]. Our
subsequent studies of the choline phospholipid metabolism
of HMECs representing different stages of breast carcino-
genesis revealed that the ‘‘malignant phospholipid pheno-
type’’ was characterized by high PC and high total choline
[10]. Consistent with our nm23 transfection study, malignant
HMECs exhibited higher PC/GPC ratios compared to mortal
and immortalized HMECs.
The nonsteroidal anti - inflammatory agent (NSAID) and
nonspecific cyclooxygenase (COX) inhibitor, indomethacin,
is known to reduce invasion and metastasis from human
breast cancer cells treated with a dose of 50 M for 18 hours
[11,12]. We observed that, following treatment with a single
high dose of 300 M indomethacin, changes in choline
phospholipid metabolism of breast cancer cells mimicked the
effects of nm23 transfection, and altered the malignant
choline phospholipid phenotype toward a less malignant
one [13]. These results suggest that 1) the differences in
choline phospholipid metabolites between nonmalignant and
malignant HMECsmay be related, in part, to the inflammatory
state of the cell, and 2) that nm23 expression may be altered
following treatment with indomethacin. Most solid tumors,
including breast cancers, exhibit inflammatory properties
characterized by increased levels of prostaglandins and other
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proinflammatory molecules that are secreted by tumor cells,
stromal cells, and specialized immune cells during inflam-
mation [14,15]. Such an upregulation of inflammatory
characteristics is not surprising in view of the similarities
between physiological conditions in injured tissue, such as
hypoxia and low extracellular pH, and the physiological
environment of solid tumors [16 – 19]. The characteristic
response of living vascularized tissue to injury is inflamma-
tion, which induces the formation of eicosanoids. Three well -
known classes of phospholipases, phospholipase A2
(PLA2), phospholipase C, and phospholipase D, participate
in the formation of free arachidonate from membrane
phospholipids in response to mechanical, chemical, and
physical stimuli [20 ]. Because arachidonic acid is derived
from membrane phospholipids, its production and utilization
in the formation of eicosanoids is closely coupled to
membrane choline phospholipid metabolism [20]. Arach-
idonic acid is converted to various eicosanoids by the action
of lipoxygenases and cyclooxygenases [21]. These eicosa-
noids impact on cell motility, invasion, vascular character-
istics and metastatic dissemination [22–24].
In this study, the relationship between COX-1 and COX-2
levels and choline phosholipid metabolites in untreated and
indomethacin treated HMECs was determined. Changes in
Nm23 protein expression levels in HMECs following treat-
ment with indomethacin were also determined. 1H NMR
spectroscopy was used to examine the effect of indometha-
cin on the phospholipid profile of five HMECs: 184-mortal, a
normal mammary epithelial cell line with a finite life span,
derived from reductionmammoplasty specimens; MCF-12A,
an immortalized, estrogen- independent, but nonmalignant
cell line, MCF-7, an estrogen-dependent, malignant cell
line, and MDA-MB-231 and MDA-MB-435, two highly
malignant, estrogen- independent cell lines. Parallel experi-
ments were performed to determine basal COX-1 and COX-
2 expression. Inducible COX expression in these cell lines
was also determined by stimulating cells with 12-O -
tetradecanoylphorbol -13-acetate (TPA). Expression of
Nm23 following the administration of 300 M indomethacin
was analyzed using western blotting. All HMECs exhibited a
significant change in choline phospholipid metabolites
following treatment with 300 M indomethacin. For the lower
dose of 50 M, only the nonmalignant cell lines and the
estrogen-dependent malignant cell line, MCF-7, displayed a
significant change in choline phospholipid metabolites
following treatment. MCF-7 is the least aggressive of the
three malignant cell lines studied. COX-1, but not COX-2,
expression levels were significantly higher in malignant
HMECs than in nonmalignant HMECs. A significant increase
in Nm23 protein expression was detected in MCF-12A and
MCF-7 cells following treatment. Highly malignant and me-
tastatic breast cancer cell lines MDA-MB-435 and MDA-
MB-231 did not exhibit a significant increase in Nm23 protein
expression. Indomethacin- induced changes in choline
compounds of HMECs were found to be cell type and
dose dependent. These results suggest that COX activity
and its inhibition can alter cell choline phosholipid meta-
bolites, and that the effect of indomethacin treatment of
HMECs may be mediated, in part, through upregulation of
nm23.
Methods
Cell Lines
The finite life span human mammary epithelial cell line,
184-mortal, was obtained from Dr. Martha Stampfer
(Lawrence Berkeley National Laboratory, Berkeley, CA)
and cultured in MEBMmedium (Clonetics, Walkersville, MD)
supplemented with growth factors [25]. The spontaneously
immortalized human mammary epithelial cell line MCF-12A,
which was established from MCF-12M mortal cells, was
obtained from American Type Culture Collection (ATCC,
Rockville, MD) and cultured in DMEM–Ham’s F-12 medium
(Sigma, St. Louis, MO) supplemented as previously
described [26]. The two human breast cancer cell lines,
MDA-MB-231 and MDA-MB-435, originally isolated from
pleural effusions of patients with breast carcinoma, were
kindly donated by Dr. R. J. Gillies and Dr. J. P. Backer,
respectively. The tumor-derived cell lines were cultured in
DMEM medium supplemented with 10% fetal bovine serum
and antibiotics (Life Technologies, Grand Island, NY). MCF-
7, an estrogen-sensitive mammary epithelial cancer cell line,
was obtained from ATCC and cultured in EMEM medium
supplemented with 10% fetal bovine serum and antibiotics
[27]. All media were supplemented with 100 U/ml penicillin
and 100 g/ml streptomycin. All cells were maintained at
378C in a humidified atmosphere containing 5% CO2.
Extraction and NMR Spectroscopy
To determine the effect of indomethacin treatment on
choline phospholipid metabolites, cells were cultured to 70%
to 80% confluency at which time they were fed with
fresh medium containing 300 M indomethacin (Sigma)
for 3 hours, or 50 M indomethacin for 18 to 24 hours.
Control cells were fed with media without indomethacin at
matching times. The cells were harvested and counted using
trypan blue exclusion to score for viability. Perchloric acid
extracts were obtained from approximately 1108 cells as
previously described [10].
Briefly, cells were trypsinized, washed twice with cold
150 mM NaCl solution, counted, and homogenized with 5 ml
of ice-cold 8% perchloric acid. The homogenates were
centrifuged at 15,000 rpm for 15 minutes at 48C and the
supernatants neutralized with 3 M K2CO3–1 M KOH buffer.
The samples were again clarified by centrifugation, treated
with 50 mg chelex (Sigma) to remove divalent ions,
lyophilized, and resuspended in 0.6 ml of D2O for NMR
analysis. Five microliters of D2O containing 0.75% 3-
( trimethylsilyl )propionic 2,2,3,3-d4 acid sodium salt (TSP)
was used as an internal standard. 1H NMR spectra of the
extracts were acquired on a 500-MHz (11.7-T/89mm)MSL
Bruker NMR spectrometer (Bruker, Billerica, MA) with a
5-mm 1H probe. NMR spectra were obtained using the
following acquisition parameters: 308 flip angle, 6000 Hz
sweep width, 4.7 seconds repetition time, 32 K block size,
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and 128 scans. The small flip angle of the radio frequency
pulse and the relatively long interpulse delay efficiently
removed saturation effects while preserving high sensitivity
of detection. Data were analyzed using Bruker software. PC,
GPC, and total choline-containing (PC+GPC+Cho) metab-
olite levels were determined and normalized to cell volume.
Cell size was determined for each cell line by trypsinizing the
cells and counting the diameter of 50 randomly selected cells
using an optical microscope. Between three and nine
independent extracts were analyzed for each dose (50 and
300 M) of indomethacin per cell line.
To determine metabolite concentrations, peak amplitudes
( I ) for Cho, PC, GPC, and total choline-containing metab-
olites (PC+GPC+Cho) were compared to that of the
internal standard TSP according to the equation:
½metabolite ¼ ATSP Imetabolite
ITSPNcellVcell ð1Þ
where [metabolite ] is the molar concentration of the
metabolite, ATSP is the number of moles of TSP in the
sample, Ncell is the cell number, and Vcell the cell volume
calculated from the radius ( r ) of the cell according to the
equation, Vcell=4 /3r
3. Peak amplitudes were used
because the line widths of the peaks were similar.
Corrections for differences in the number of protons were
not required, because the number of protons in the choline
compounds was the same as the number of protons in TSP.
For Eq. (1) to be valid, it is necessary that spectra are fully
relaxed, as in this study, or to correct for saturation. PC/GPC
ratios of untreated cells were determined by pooling PC/
GPC values of the control sets obtained for both doses (50
and 300 M) of indomethacin.
Western Blotting
Cells were plated and grown on 100-mm dishes until 80%
confluent. To determine basal and inducible levels of the
COX enzymes, control cells were fed with fresh medium and
TPA-stimulated cells with medium containing 40 nM TPA
for 3 hours. Cells were rinsed with phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO47H2O,
1.4 mM KH2PO4, pH 7.4), scraped, and collected in a lysis
buffer containing 100 mM Tris–HCl pH 8.0, 150 mM NaCl,
1 mM EDTA, 1% Tween-20, and protease inhibitors
(Boehringer Mannheim, Indianapolis, IN). Cell lysates were
homogenized on ice for 20 seconds. Lysates were centri-
fuged at 14,000 rpm to sediment particulate material. Protein
concentrations were estimated using the Bio-Rad DC assay
(Bio-Rad, Melville, NY), which is based on the method of
Lowry [28]. Equal amounts of supernatant (40 to 100 g
protein/ lane) were loaded and resolved on a 10% reducing
SDS-PAGE as described by Laemmli [29]. Proteins were
then transferred to an Immobilon-P membrane (Millipore,
Bedford, MA) according to Towbin [30]. The uniformity of
transfer was verified by staining with Ponceau-S solution
(Sigma). After blocking in 5% milk overnight, the membrane
was separately probed with antibodies to COX-1 (rabbit
polyclonal ) and COX-2 (rabbit polyclonal ). These anti-
bodies are specific for COX-1 or COX-2 and do not cross-
react with each other (Oxford Biomedical Research, Oxford,
MI). The membrane was then incubated with a horseradish
peroxidase–conjugated anti - rabbit antibody ( from donkey)
and the blots were developed using an enhanced chem-
iluminescence (ECL) system (Amersham Pharmacia Bio-
tech, Piscataway, NJ) and exposed to Kodak (Rochester,
NY) biomax film. Ovine COX-1 and COX-2 were used as
standards (Oxford Biomedical Research, Oxford, MI). For
semiquantitation of COX-1 and COX-2 enzymes, each
experiment was repeated thrice under similar experimental
conditions. The bands were quantified using NIH- Image
1.61 by comparison with a calibration curve of COX-1 and
COX-2 standards loaded on the same gel as the samples.
The band intensities were normalized to the total amount of
protein loaded in each lane of the gel.
Nm23 expression was analyzed in the presence and
absence of indomethacin in MCF-12A, MCF-7, MDA-MB-
Figure 1. Proton spectra of MCF-7 cells. Proton spectra are from (A )
untreated cells, (B ) cells treated with 50 M indomethacin for 18 hours, and
(C ) cells treated with 300 M indomethacin for 3 hours. Spectra were
acquired with 308 flip angle, 6000 Hz sweep width, 4.7 seconds repetition time,
32 K block size and 128 scans. Spectra are expanded to display signals from
the phosphorylcholine (PC ), glycerophosphorylcholine (GPC ), and choline
(Cho ) region only.
Figure 2. Proton spectra of MDA-MB -435 cells. Proton spectra are from (A )
untreated cells, (B ) cells treated with 50 M indomethacin for 18 hours, and
(C ) cells treated with 300 M indomethacin for 3 hours. Spectra were
acquired with 308 flip angle, 6000 Hz sweep width, 4.7 seconds repetition time,
32 K block size and 128 scans. Spectra are expanded to display signals from
the phosphorylcholine (PC), glycerophosphorylcholine (GPC ), and choline
(Cho ) region only.
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231, and MDA-MB-435 cells. Cell lysates were prepared at
various time points after treatment with 300 M indometha-
cin. Total protein (40 to 60 g) was resolved on a 15% SDS-
PAGE and then blotted onto a nitrocellulose membrane
(Schleicher & Schuell, Keene, NH). The membranes were
probed with a polyclonal antibody (Neomarkers, Fremont,
CA) that cross-reacts with both 17- and 18.5-kDa isoforms
of nm23. After probing for Nm23 protein expression, the
membranes were stripped and reprobed with monoclonal
anti– -actin antibody (Sigma). The Nm23 band intensities
were normalized to actin. The fold induction was calculated
by measuring the increase in Nm23 expression in indome-
thacin- treated cells compared to corresponding untreated
cells (n=3 to 5).
Statistical Analysis
Data are expressed as mean±SE. The statistical signifi-
cance of differences in treatment between untreated and
indomethacin- treated cells was determined using the
unpaired t test ( two- tailed). The correlation between total
choline levels, PC/GPC ratios and COX-1 levels was
examined by Spearman correlation coefficient. P values
.05 were considered significant.
Results
The Effect of Indomethacin on the Choline Phospholipid
Profiles
Representative proton spectra of MCF-7 cells (A)
untreated, (B) treated with 50 M indomethacin for
18 hours, and (C) treated with 300 M indomethacin for 3
hours are shown in Figure 1. Following treatment with
indomethacin, GPC levels were elevated, whereas PC levels
were reduced. A similar set of spectra from MDA-MB-435
cells (A) untreated, (B) treated with 50 M indomethacin for
22 hours, and (C) treated with 300 M indomethacin for
3 hours are shown in Figure 2. In contrast to the MCF-7 cells
in Figure 1B, MDA-MB-435 cells did not show any change in
choline phosholipid metabolites at the low dose of 50 M
Figure 4. Basal and TPA-stimulated expression of COX-1 and COX-2 in
human breast cell lines. C — Untreated HMECs, T — HMECs treated with
40 nM TPA for 3 hours. Lane 1, 184-mortal (184-M); Lane 2, 184-mortal+40
nM TPA; Lane 3, MCF-12A; Lane 4, MCF-12A+40 nM TPA; Lane 5, MCF-7;
Lane 6, MCF-7+40 nM TPA; Lane 7, MDA-MB-231; Lane 8, MDA-MB-
231+40 nM TPA; Lane 9, MDA-MB-435; Lane 10, MDA-MB-435+40 nM TPA;
Lane 11, COX-1 or COX-2 standard. Equal amounts of total protein were
loaded per lane on a 10% reducing SDS-PAGE.
Figure 3. Fractional decrease in PC /GPC ratios in treated HMECs compared
to their respective controls. Control cells (5 ), HMECs treated with 50 M
indomethacin for 18 to 24 hours ( ), or HMECs treated with 300 M
indomethacin for 3 hours (& ). Data are expressed as average±SE
( * represents P.05; ** represents P.01 ). Choline metabolite levels in
184 -mortal cells treated with 300 M indomethacin for 3 hours were not
determined. The fractional decrease in PC /GPC ratio for each cell line was
calculated by dividing the mean PC /GPC ratio for treated cells at a given
dosage of indomethacin by the mean PC /GPC ratio obtained for the pooled
controls. Statistical analyses were performed using actual PC /GPC values
and not normalized values.
5

Figure 5. Relationship between PC/GPC ratios, total choline levels and COX-
1 expression in HMECs. (A) Correlation graph between PC/GPC ratios versus
COX-1 expression in HMECs (P.00118). (B) Correlation graph between total
choline levels versus COX-1 expression in HMECs (P.000006). Cell lines
are represented as (6) nonmalignant HMECs and (o) malignant HMECs.
Data are obtained from three cell extracts per cell line.
Figure 6. Nm23 protein expression in HMECs. (A) Nm23 expression in MCF-7
cells. Cells were incubated with 300 M indomethacin for various time periods
at 378C as indicated. Controls were cultured in the absence of indomethacin.
Actin levels are shown for comparison. (B) Fold induction in Nm23 expression
in HMECs (30 minutes to 1 hour) after administration of 300 M indomethacin.
Cell lines are represented as (5) MCF-12A cells, (&) MCF-7 cells, (&) MDA-
MB-231 cells, and (&)MDA-MB-435 cells. Data are expressed as ave-
rage±SE (*P.05). Data are obtained from three to five extracts per cell line.
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indomethacin (Figure 2B ). Data for the fractional decrease
in PC/GPC ratio following treatment with 50 and 300 M
indomethacin for each cell line are summarized in Figure 3. A
significant decrease of PC/GPC ratios was observed for
both malignant and nonmalignant HMECs when treated with
300 M indomethacin for 3 hours. Only MCF-7 cells and the
nonmalignant HMECs showed a significant decrease of PC/
GPC ratios when treated with 50 M indomethacin for 18 to
24 hours.
COX-1 and COX-2 Expression
Western blots of COX-1 and COX-2 protein expression
for the cell lines are shown in Figure 4. The malignant cell
lines displayed higher basal levels of COX-1 expression
compared to the normal and immortalized cell line (MDA-
MB-231MDA-MB-435>MCF-7>MCF-12A>184-mortal ).
The pattern of COX-2 expression, however, was unlike that
of COX-1. Only 184-mortal cells and the malignant cell line
MDA-MB-231 exhibited basal COX-2 expression. Basal
levels of COX-2 were undetectable for MDA-MB-435,
MCF-7, and MCF-12A cells. Following stimulation of cells
with 40 nM of TPA for 3 hours, MDA-MB-231, MCF-12A,
and 184-mortal showed an increase in COX-2 expression
from basal levels, but neither MDA-MB-435 nor MCF-7
cells showed inducible COX-2 expression. No significant
changes in COX-1 levels were detected for the HMECs
following stimulation with TPA.
The relationship between the amount of total choline-
containing phospholipids (PC, GPC, and choline), PC/GPC
ratios, and their corresponding COX-1 levels for the HMECs
is illustrated in Figure 5. A significant positive correlation was
observed between PC/GPC ratio and COX-1 expression
(Figure 5A ) as well as between total choline-containing
phospholipids (PC, GPC, and choline) and COX-1 expres-
sion (Figure 5B ).
Effect of Indomethacin on Nm23 Expression
Basal and indomethacin- induced Nm23 protein (not
isoform specific ) expression for MCF-7 cells is shown in
Figure 6A. The nonmalignant immortalized cell line MCF-
12A and the estrogen-dependent, malignant cell line MCF-7
expressed higher basal levels of Nm23 compared to the
highly malignant cell lines MDA-MB-231 and MDA-MB-435
(data not shown). Unlike the highly malignant cell lines, both
MCF-12A and MCF-7 cells showed significant induction
of Nm23 expression within 1 hour following treatment with
300 M indomethacin as shown in Figure 6B.
Discussion
Elevated COX-1 Expression is Associated with Elevated
PC and Total Choline Levels in HMECs
Of the two forms of COX, COX-1 is constitutive and
COX-2 is inducible [31,32]. Current consensus is that both
COX-1 and COX-2 are upregulated for several types of
malignant cells and COX-2 is inappropriately induced
[33,34]. Characterization of COX-1 and COX-2 expression
in our study revealed that the malignant HMECs exhibited
significantly higher levels of COX-1 expression compared to
the nonmalignant normal 184-mortal cells and immortalized
MCF-12A cells. Basal COX-2 expression was variable in
the malignant HMECs, as was the inducible expression of
COX-2, determined by treating cells with TPA. The
expression of inducible COX-2 in 184-mortal cells was
probably due to the presence of growth factors in the
medium, which maintain these cells in a stimulated state.
Unlike COX-1, neither basal nor inducible COX-2 expres-
sion was related to the phospholipid phenotype observed in
the cell lines. These results are consistent with other studies
which suggest that COX-1 mRNA levels are consistently
elevated in breast cancer cells whereas the elevation of
COX-2 is variable [35]. Similar patterns of COX-2 expres-
sion for MDA-MB-231 and MDA-MB-435 cells have also
been observed by Gilhooly and Rose [36].
Our results are also consistent with the study by Hanson
and DeLeo [37], in which long-wave ultraviolet radiation
stimulation of human and mouse fibroblasts led to an
increase in the release of PC and, to a lesser extent, GPC.
An accompanying elevation of COX, but not lipoxygenase,
metabolites was detected. Cancer cells are continually
subjected to a stressed environment characterized by
hypoxia and extracellular acidosis, both during growth, and
during treatment [16,38]. Our working hypothesis is that the
increased COX-1 expression in malignant cells, compared
to nonmalignant cells, may be related to this sustained
exposure to stress. Increased COX-1 activity may produce a
proportionately higher number of prostanoids that may, in
turn, influence the invasive and metastatic behavior [22,23],
as well as the vascular characteristics, of the primary and the
disseminated tumor [39]. This sustained stimulation of cells
may be responsible for the differences in phospholipid
profiles between malignant and nonmalignant HMECs.
In human breast tumors, COX-1 expression has been
found to be mainly confined to stroma whereas COX-2
expression was detected within tumor cells and occasion-
ally in stromal cells [40]. This differential expression of
COX-1 and COX-2 within a tumor suggests that both
autocrine and paracrine mechanisms may be responsible
Figure 7. Schematic diagram of the changes in PC/GPC ratio in untreated
malignant HMECs or following nm23 transfection or indomethacin treatment.
Treatment with the COX inhibitor, indomethacin, also induces increased
Nm23 protein expression levels.
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for the development of the tumor type. Depending on the
stimuli, either COX-1, or COX-2, or both enzymes may be
overexpressed. Alternatively, the expression of one COX
isoform may influence the expression of the other isoform.
Narko et al. [41] have shown that COX-1 can solely
contribute to the tumorigenicity of a cell type. Transfection of
ECV-304, a spontaneously transformed endothelial cell line,
with COX-1, resulted in the formation of tumors in athymic
mice. In addition, experiments using Min (multiple intestinal
neoplasia) mice have demonstrated that Min mice deficient
in either COX-1 or COX-2 genes show a decreased
incidence of intestinal tumorigenesis suggesting that both
enzymes play a role in promoting tumorigenesis [42,43].
Although we have only examined COX-1 and COX-2
expression in this study, the impact of other enzymes of the
choline cycle on the cellular choline phospholipid profile
should also be considered. For instance, increased choline
kinase activity has been observed in patients with colon
carcinoma [44], and elevated PLA2 levels have been
detected in the serum of patients with cancer [45] as well
as in ras - transformed HMECs [46]. An increase in lip-
oxygenase products has also been detected in patients with
breast cancer [15]. Preliminary data from other groups
suggest that activation of phospholipases by growth factors
and oncogene products could result in high constitutive
intracellular pools of PC within these cells [47–49]. These
observations suggest that changes in activity, expression,
and synthesis of enzymes that influence the inflammatory
pathway also affect choline phosholipid metabolites.
Effect of Indomethacin on the Choline Phospholipid Profile
of HMECs
The PC/GPC ratio decreased significantly following
treatment with indomethacin. Of the three malignant cell
lines, MCF-7 cells were the most sensitive, exhibiting a
significant decrease of PC/GPC ratio for the 50 M dose,
which was not observed for MDA-MB-231 and MDA-MB-
435 cells. The nonmalignant cell lines were more sensitive
than the malignant cell lines to indomethacin, exhibiting a
further reduction in PC following treatment. As mentioned
earlier, changes in NMR spectra of the malignant HMECs
following treatment with indomethacin were very similar to
changes observed in MDA-MB-435 cells following trans-
fection with nm23 [5 ] and were characteristic of a decreased
malignant phenotype.
Changes in choline phospholipids have been observed
during tumor progression, in immortalized or oncogene
transformed cell lines, and during drug therapy [50–52].
Comparison of 31P NMR spectra from a normal breast
epithelial cell strain (76N) with three breast cancer cell lines
(21PT, 21NT and 21MT-2) established from the same
patient, showed that PC levels were significantly higher in the
breast cancer cell lines [50]. These changes were reflected
as a significant decrease in the GPC/PC ratios in the primary
(21PT, 21NT) and metastatic tumor (21MT-2) cell lines
when compared with the normal cell strain. 21MT-2, the
metastatic cell line, also showed a significant decrease in
GPC/PC ratio compared with the primary breast cell lines,
21PT and 21NT. Similarly, a high PC/GPC ratio was
observed for a series of human tumor lines of neuronal
origin when compared with primary cultures of the central
and peripheral nervous system or to normal tissue obtained
from brain biopsy extracts [51]. Thus, malignant trans-
formation is accompanied with an increased PC/GPC ratio.
Conversely, growth arrest has been shown to reduce the
PC/GPC ratio. Treatment of MCF-7 cells with tumor
necrosis factor -alpha, which induces cell cycle arrest and
apoptosis, resulted in a decrease of PC [52]. An increase in
GPC was observed when rat Schwann cells were trans-
formed by H- ras, which causes growth arrest in these cells
[51]. In addition to COX inhibition, indomethacin has been
observed to induce cell cycle arrest [53,54], apoptosis
[55,56], and potentiate the effects of differentiating agents
[57]. These effects have been shown to occur either
through, or independently of, the COX pathway [58], but
are consistent with the changes in PC/GPC observed in the
spectra. Although we did not observe significant changes in
cell viability using trypan blue exclusion following treatment
with indomethacin, further experiments are currently under-
way to determine the effect of indomethacin on cell cycle
arrest and apoptosis for our panel of HMECs.
Effect of Indomethacin on Nm23 Expression in HMECs
Nm23 proteins, also known as nucleoside diphosphate
kinases, are phosphotransferases that are implicated in cell
growth and differentiation [59]. Here we have shown that in
HMECs, indomethacin enhances the expression of Nm23,
which is also a metastasis suppressor protein [7 ]. Induction
of Nm23 expression by indomethacin is consistent with the
phospholipid changes seen in HMECs following treatment
with indomethacin. The two cell lines, MCF-12A and MCF-
7, which were most sensitive to indomethacin treatment, as
indicated by a significant change in their phospholipid
profiles, also showed a significant increase in Nm23
expression. Other studies have shown that Nm23 expression
is downregulated in the presence of proinflammatory
molecules such as PGE2, tumor necrosis factor-alpha, and
interferon-gamma in B16-F10 murine melanoma cells [60].
Inflammatory responses and metastasis suppressor protein
expression may be linked through an Nm23-mediated
phospholipid signaling pathway [61].
In conclusion, as outlined in the schematic in Figure 7, the
significant relationship observed between the PC/GPC ratio
obtained from 1H NMR spectra of breast cancer cells and
their COX-1 expression, and the decrease in PC/GPC ratio
following indomethacin treatment, suggests that both the
initial phospholipid profiles, as well as changes observed
following treatment with indomethacin may be related to
COX activity and Nm23 expression. The precise mecha-
nisms underlying the increase in GPC relative to PC
following treatment with indomethacin are yet to be
delineated. Indomethacin is used to treat rheumatoid
arthritis, with daily doses of 100 to 150 mg given over a
period of 4 to 6 weeks [62,63]. These doses are comparable
with the concentrations of 50 to 300 M used in our study.
Our NMR data, and the enhanced expression of Nm23
414 Indomethacin Alters Choline Metabolites and Nm23 Levels Natarajan et al.
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following indomethacin, support further investigations of
NSAIDs in cancer therapy for chemoprevention and for the
treatment of metastatic disease. Further studies are also
necessary to understand mechanisms by which anti -
inflammatory agents impact metastasis suppressor path-
ways and the role of oncogenes in activating inflammatory
pathways.
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